440 - Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by Fc-engineering of IgA antibody against the epidermal growth factor receptor. - Rösner, T.; Kretschmer, A.; Lohse, S.; Meyer, S.; Jansen, J.H.M.; Möginger, U.; Sondermann, P.; Kolarich, D.; Leusen, J.H.W.; Valerius, T. (European Journal of Cancer, 2016)